Abby Willcox1, Lucy Culliford1, Lucy Ellis1, Chris A Rogers1, Angela Cree2, Usha Chakravarthy3, Sarah Ennis4, Francine Behar-Cohen5,6,7, Barnaby C Reeves1, Sobha Sivaprasad8, Andrew Lotery9. 1. Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Royal Infirmary, University of Bristol, Bristol, BS2 8HW, UK. 2. Department of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK. 3. Centre for Vision Sciences, The Queen's University of Belfast, Belfast, BT12 6BA, UK. 4. Department of Human Genetics and Genomics Medicine, University of Southampton, Southampton, SO16 6YD, UK. 5. University of Lausanne, Lausanne, Switzerland. 6. Teams 1 and 17, Centre de Recherche des Cordeliers, UMR 1138, Sorbonne Universités UPMC, Université Paris 06, Paris, France. 7. Centre de Recherche des Cordeliers, UMR 1138, Sorbonne Paris Cité, Université Paris Descartes, Paris, France. 8. NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, EC1V 2PD, UK. Sobha.Sivaprasad@moorfields.nhs.uk. 9. Department of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK. a.j.lotery@soton.ac.uk.
Abstract
AIMS: Chronic central serous chorioretinopathy (CSCR) is poorly understood. Fluid accumulates in the subretinal space and retinal pigment epitheliopathy and neurosensory atrophy may develop. Permanent vision loss occurs in approximately one third of cases. There are no effective treatments for CSCR. Recent studies have shown the mineralocorticoid receptor antagonist, eplerenone, to be effective in resolving subretinal fluid and improving visual acuity. This trial aims to compare the safety and efficacy of eplerenone in patients with CSCR in a double-masked randomised placebo-controlled trial. METHODS: Patients are randomised 1:1 to receive eplerenone with usual care or placebo with usual care for 12 months; 25 mg per day for 1 week, then 50 mg per day up to 12 months (unless discontinued for safety or resolution of CSCR). Key eligibility criteria are: age 18-60 years, one eye with CSCR for ≥4 months duration, best-corrected visual acuity (BCVA) >53 and <86 letters and no previous treatment. The primary outcome is BCVA at 12 months. Secondary outcomes include resolution of subretinal fluid, development of macular atrophy, subfoveal choroidal thickness, changes in low luminance visual acuity, health-related quality of life and safety. CONCLUSIONS: Recruitment is complete but was slower than expected. We maintained the eligibility criteria to ensure participants had 'true' CSCR and recruited additional centres. Effective distribution of the investigational medicinal product (IMP) was achieved by implementing a database to manage ordering and accountability of IMP packs. The results will provide adequately powered evidence to inform clinical decisions about using eplerenone to treat patients with CSCR.
AIMS: Chronic central serous chorioretinopathy (CSCR) is poorly understood. Fluid accumulates in the subretinal space and retinal pigment epitheliopathy and neurosensory atrophy may develop. Permanent vision loss occurs in approximately one third of cases. There are no effective treatments for CSCR. Recent studies have shown the mineralocorticoid receptor antagonist, eplerenone, to be effective in resolving subretinal fluid and improving visual acuity. This trial aims to compare the safety and efficacy of eplerenone in patients with CSCR in a double-masked randomised placebo-controlled trial. METHODS: Patients are randomised 1:1 to receive eplerenone with usual care or placebo with usual care for 12 months; 25 mg per day for 1 week, then 50 mg per day up to 12 months (unless discontinued for safety or resolution of CSCR). Key eligibility criteria are: age 18-60 years, one eye with CSCR for ≥4 months duration, best-corrected visual acuity (BCVA) >53 and <86 letters and no previous treatment. The primary outcome is BCVA at 12 months. Secondary outcomes include resolution of subretinal fluid, development of macular atrophy, subfoveal choroidal thickness, changes in low luminance visual acuity, health-related quality of life and safety. CONCLUSIONS: Recruitment is complete but was slower than expected. We maintained the eligibility criteria to ensure participants had 'true' CSCR and recruited additional centres. Effective distribution of the investigational medicinal product (IMP) was achieved by implementing a database to manage ordering and accountability of IMP packs. The results will provide adequately powered evidence to inform clinical decisions about using eplerenone to treat patients with CSCR.
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Roy W Beck; Maureen G Maguire; Neil M Bressler; Adam R Glassman; Anne S Lindblad; Frederick L Ferris Journal: Ophthalmology Date: 2007-10 Impact factor: 12.079
Authors: David M Brown; Mark Michels; Peter K Kaiser; Jeffrey S Heier; Judy P Sy; Tsontcho Ianchulev Journal: Ophthalmology Date: 2009-01 Impact factor: 12.079
Authors: Carl Schubert; Anders Pryds; Shemin Zeng; Yajing Xie; K Bailey Freund; Richard F Spaide; John C Merriam; Irene Barbazetto; Jason S Slakter; Stanley Chang; Inger C Munch; Arlene V Drack; Jasmine Hernandez; Suzanne Yzer; Joanna E Merriam; Allan Linneberg; Michael Larsen; Lawrence A Yannuzzi; Robert F Mullins; Rando Allikmets Journal: Hum Mutat Date: 2014-07 Impact factor: 4.700